If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLSAI.L Regulatory News (LSAI)

  • There is currently no data for LSAI

Update in relation to Placing

9 Dec 2014 07:00

RNS Number : 1848Z
Proxama PLC
09 December 2014
 

THIS ANNOUNCEMENT IS RESTRICTED AND IT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, THE REPUBLIC OF IRELAND OR AUSTRALIA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Proxama Plc

("Proxama" or the "Group" or the "Company")

Update in relation to Placing

On 4 November 2014, Proxama, the global platform provider of mobile proximity marketing, mobile wallet and payment solutions, announced the terms of a conditional placing of up to 160,000,000 new ordinary shares of 1 pence each in the Company at a price of 2.5 pence per share to raise approximately £4.0 million before expenses (the "Placing").

On 28 November 2014, Proxama announced the completion of the first stage of the Placing (the "Tranche One Placing"), pursuant to which a total of 130,925,040 new Ordinary Shares were subscribed by institutional and other investors (including certain directors of the Company), raising £3,273,126 for the Company before expenses.

Following completion of the acquisition of Aconite Technologies Limited, announced by the Company on 5 December 2014, Proxama is please to announce that all conditions to completion of the second and third tranches to the Placing (other than that relating Admission) have now been satisfied or waived. Accordingly, the Company has conditionally allotted a total of 29,074,960 new Ordinary Shares to placees subscribing for new Ordinary Shares pursuant to the second and third tranches of the Placing. Application has been made to the London Stock Exchange for those new Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will become effective on 10 December 2014.

 

Following Admission, the Company will have 1,018,466,932 Ordinary Shares in issue with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares currently held in treasury. The total number of voting rights in the Company therefore will be 1,018,466,932 and this figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

 

For further Information:

 

Proxama PLC

Neil Garner, Chief Executive

Miles Quitmann, Chief Commercial Officer

Coen van Breda, Chief Financial Officer

020 7959 2298

 

Peel Hunt LLP

(Nominated Adviser and Broker)

Richard Kauffer

Edward Fox

020 7418 8900

Cadogan PR

Alex Walters

0207 499 5002

07771713608

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOETPBLTMBTMBPI
Date   Source Headline
11th May 20219:05 amRNSSecond Price Monitoring Extn
11th May 20219:00 amRNSPrice Monitoring Extension
6th May 20217:00 amRNSResult of Broker Option
5th May 20212:06 pmRNSSecond Price Monitoring Extn
5th May 20212:00 pmRNSPrice Monitoring Extension
4th May 202111:05 amRNSSecond Price Monitoring Extn
4th May 202111:00 amRNSPrice Monitoring Extension
4th May 20219:05 amRNSSecond Price Monitoring Extn
4th May 20219:00 amRNSPrice Monitoring Extension
4th May 20217:00 amRNSProposed Fundraise of up to £3.85m - Notice of GM
23rd Apr 20212:05 pmRNSSecond Price Monitoring Extn
23rd Apr 20212:00 pmRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSFinal Results for the year ended 31 December 2020
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Feb 202111:00 amRNSPrice Monitoring Extension
19th Feb 20213:36 pmRNSTR-1 Notification of major holdings
11th Feb 202111:06 amRNSSecond Price Monitoring Extn
11th Feb 202111:00 amRNSPrice Monitoring Extension
11th Feb 20219:05 amRNSSecond Price Monitoring Extn
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:00 amRNSTrading Update and Directorate Changes
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
28th Jan 20214:41 pmRNSSecond Price Monitoring Extn
28th Jan 20214:36 pmRNSPrice Monitoring Extension
21st Jan 20214:41 pmRNSSecond Price Monitoring Extn
21st Jan 20214:36 pmRNSPrice Monitoring Extension
20th Jan 20214:40 pmRNSSecond Price Monitoring Extn
20th Jan 20214:35 pmRNSPrice Monitoring Extension
18th Dec 20207:00 amRNSHolding(s) in Company
17th Dec 20204:41 pmRNSSecond Price Monitoring Extn
17th Dec 20204:35 pmRNSPrice Monitoring Extension
16th Dec 20204:41 pmRNSSecond Price Monitoring Extn
16th Dec 20204:36 pmRNSPrice Monitoring Extension
14th Dec 20207:00 amRNSPotential Defamation Action Against the Company
30th Nov 20207:00 amRNSNew Contract Win and Trading Update
5th Nov 20203:44 pmRNSHolding(s) in Company
30th Oct 20207:00 amRNSIssue of shares to directors in lieu of fees & TVR
1st Oct 20207:00 amRNSAppointment of Nominated Adviser
17th Sep 202012:43 pmRNSHalf-year Report - Replacement
15th Sep 20207:00 amRNSHalf-year Report
1st Sep 20209:05 amRNSSecond Price Monitoring Extn
1st Sep 20209:00 amRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSContract
27th Jul 20207:00 amRNSTrading Update
3rd Jul 202011:05 amRNSSecond Price Monitoring Extn
3rd Jul 202011:00 amRNSPrice Monitoring Extension
1st Jul 202010:02 amRNSIssue of Equity and Total Voting Rights
16th Jun 202010:36 amRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.